Home Categories Biochemical Engineering Degarelix?
M2059835

Degarelix? , ≥99% , 214766-78-6

Synonym(s):
Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(L-hydroorotyl)-D4Aph(carbamoyl)-Leu-ILys-Pro-DAla-NH2 acetate salt;ASP3550 acetate;FE 200486;FE200486

CAS NO.:214766-78-6

Empirical Formula: C82H103ClN18O16

Molecular Weight: 1632.26

MDL number: MFCD05860888

EINECS: 807-277-4

Pack Size Price Stock Quantity
2mg RMB1358.40 In Stock
5mg RMB2240.00 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Density  1.325±0.06 g/cm3(Predicted)
storage temp.  Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility  DMSO:10.0(Max Conc. mg/mL);6.13(Max Conc. mM)
H2O:25.0(Max Conc. mg/mL);15.32(Max Conc. mM)
pka 10.38±0.40(Predicted)
form  Solid
color  White to off-white
Sequence Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-4-Aph(Hor)-4-D-Aph(Cbm)-Leu-Lys(ipr)-Pro-D-Ala-NH2
InChIKey MEUCPCLKGZSHTA-XYAYPHGZSA-N

Description and Uses

Antagonists of GnRH have proven to be an effective therapy for hormonally regulated cancers, such as prostate and some types of breast. As analogs of GnRH, they bind competitively and reversibly to GnRH receptors in the pituitary gland, thereby blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In men, the reduction of LH triggers the ablation of testosterone secretion from the testes, and these castration-like levels have been essential in the effective management of advanced prostate cancer. In comparison to GnRH agonists, antagonists do not suffer from a potential flare of the disease as a result of an initial stimulation of the hypothalamic-pituitary-gonadal axis prior to down-regulation of the GnRH receptor. Moreover, GnRH antagonists provide beneficial effects more rapidly postdosing and result in a more efficient suppression of gonadotropin levels. With this in mind, degarelix acetate has been launched as a third-generation GnRH antagonist for the treatment of prostate cancer, and it joins other third-generation agents, ganirelix and cetronelix, on the market.

Advanced hormone-dependent prostate carcinoma

Safety

Symbol(GHS) 
GHS08
Signal word  Danger
Hazard statements  H360
Hazardous Substances Data 214766-78-6(Hazardous Substances Data)

RELATED PRODUCTS